Log in | Register

Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial

Jan J. De Waele| S. Carrette| M. Carlier| V. Stove| J. Boelens| G. Claeys| I. Leroux-Roels| E. Hoste| P. Depuydt| J. Decruyenaere| A. G. Verstraete
Original
Volume 40, Issue 3 / March , 2014

Pages 380 - 387

Abstract

Purpose

There is variability in the pharmacokinetics (PK) of antibiotics (AB) in critically ill patients. Therapeutic drug monitoring (TDM) could overcome this variability and increase PK target attainment. The objective of this study was to analyse the effect of a dose-adaption strategy based on daily TDM on target attainment.

Methods

This was a prospective, partially blinded, and randomised controlled trial in patients with normal kidney function treated with meropenem (MEM) or piperacillin/tazobactam (PTZ). The intervention group underwent daily TDM, with dose adjustment when necessary. The predefined PK/pharmacodynamic (PK/PD) target was 100 % fT>4MIC [percentage of time during a dosing interval that the free (f) drug concentration exceeded 4 times the MIC]. The control group received conventional treatment. The primary endpoint was the proportion of patients that reached 100 % fT>4MIC and 100 % fT>MIC at 72 h.

Results

Forty-one patients (median age 56 years) were included in the study. Pneumonia was the primary infectious diagnosis. At baseline, 100 % fT>4MIC was achieved in 21 % of the PTZ patients and in none of the MEM patients; 100 % fT>MIC was achieved in 71 % of the PTZ patients and 46 % of the MEM patients. Of the patients in the intervention group, 76 % needed dose adaptation, and five required an additional increase. At 72 h, target attainment rates for 100 % fT>4MIC and 100 % fT>MIC were higher in the intervention group: 58 vs. 16 %, p = 0.007 and 95 vs. 68 %, p = 0.045, respectively.

Conclusions

Among critically ill patients with normal kidney function, a strategy of dose adaptation based on daily TDM led to an increase in PK/PD target attainment compared to conventional dosing.

Keywords

References

  1. Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, Investigators EIGo (2009) International study of the prevalence and outcomes of infection in intensive care units. JAMA 302:2323–2329
    • View reference on PubMed
    • View reference on publisher's website
  2. Antonelli M, Bonten M, Cecconi M, Chastre J, Citerio G, Conti G, Curtis JR, Hedenstierna G, Joannidis M, Macrae D, Maggiore SM, Mancebo J, Mebazaa A, Preiser JC, Rocco P, Timsit JF, Wernerman J, Zhang H (2013) Year in review in Intensive Care Medicine 2012. II: pneumonia and infection, sepsis, coagulation, hemodynamics, cardiovascular and microcirculation, critical care organization, imaging, ethics and legal issues. Intensive Care Med 39:345–364
  3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165–228
  4. Pletz MW, Lipman J (2013) Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Med 39:1322–1324
  5. Roberts JA, Kirkpatrick CM, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 64:142–150
    • View reference on PubMed
    • View reference on publisher's website
  6. Roberts JA, Roberts MS, Robertson TA, Dalley AJ, Lipman J (2009) Piperacillin penetration into tissue of critically ill patients with sepsis–bolus versus continuous administration? Crit Care Med 37:926–933
    • View reference on PubMed
    • View reference on publisher's website
  7. Aubert G, Carricajo A, Coudrot M, Guyomarc’h S, Auboyer C, Zeni F (2010) Prospective determination of serum ceftazidime concentrations in intensive care units. Ther Drug Monit 32:517–519
    • View reference on PubMed
    • View reference on publisher's website
  8. Blondiaux N, Wallet F, Favory R, Onimus T, Nseir S, Courcol RJ, Durocher A, Roussel-Delvallez M (2010) Daily serum piperacillin monitoring is advisable in critically ill patients. Int J Antimicrob Agents 35:500–503
    • View reference on PubMed
    • View reference on publisher's website
  9. Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Vincent JL, Wallemacq P, Jacobs F (2010) Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 14:R126
    • View reference on PubMed
    • View reference on publisher's website
  10. Goncalves-Pereira J, Povoa P (2011) Antibiotics in critically ill patients—a systematic review of the pharmacokinetics of beta-Lactams. Crit Care 15:R206
    • View reference on PubMed
    • View reference on publisher's website
  11. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840–851 (quiz 859)
    • View reference on PubMed
    • View reference on publisher's website
  12. Shekar K, Fraser JF, Roberts JA (2013) Can optimal drug dosing during ECMO improve outcomes? Intensive Care Med 39:2237
  13. Udy AA, Roberts JA, Lipman J (2013) Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med 9:2070–2082
  14. Kromdijk W, Sikma MA, van den Broek MP, Beijnen JH, Huitema AD, de Lange DW (2013) Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique. [letter]. Intensive Care Med 39(5):977–978
  15. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J (2010) First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35(2):156–163
  16. Carlier M, Carrette S, Roberts JA, Stove V, Verstraete AG, Hoste E, Decruyenaere J, Depuydt P, Lipman J, Wallis SC, De Waele JJ (2013) Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care 17:R84
    • View reference on PubMed
    • View reference on publisher's website
  17. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ (2013) Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis 56:272–282
    • View reference on PubMed
    • View reference on publisher's website
  18. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J (2013) Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 56:236–244
    • View reference on PubMed
    • View reference on publisher's website
  19. Troger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-Boger SM (2012) Decreased meropenem levels in intensive care unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents 40:370–372
    • View reference on PubMed
    • View reference on publisher's website
  20. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA (2012) Subtherapeutic initial beta-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 142:30–39
    • View reference on PubMed
    • View reference on publisher's website
  21. Hayashi Y, Lipman J, Udy AA, Ng M, McWhinney B, Ungerer J, Lust K, Roberts JA (2013) beta-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia. Int J Antimicrob Agents 41:162–166
    • View reference on PubMed
    • View reference on publisher's website
  22. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J (2010) Augmented renal clearance in the intensive care unit: an illustrative case series. Int J Antimicrob Agents 35:606–608
    • View reference on PubMed
    • View reference on publisher's website
  23. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F (2012) Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 56:2129–2131
    • View reference on PubMed
    • View reference on publisher's website
  24. van Loon HJ, Vriens MR, Fluit AC, Troelstra A, van der Werken C, Verhoef J, Bonten MJM (2005) Antibiotic rotation and development of gram-negative antibiotic resistance. Am J Respir Crit Care Med 171:480–487
    • View reference on PubMed
    • View reference on publisher's website
  25. Roberts JA, Kirkpatrick CM, Roberts MS, Dalley AJ, Lipman J (2010) First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents 35:156–163
    • View reference on PubMed
    • View reference on publisher's website
  26. Shimamoto Y, Fukuda T, Tanaka K, Komori K, Sadamitsu D (2013) Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis. Intensive Care Med 39:1247–1252
  27. Roberts JA, Joynt GM, Choi GY, Gomersall CD, Lipman J (2012) How to optimise antimicrobial prescriptions in the intensive care unit: principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents 39:187–192
    • View reference on PubMed
    • View reference on publisher's website
  28. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
    • View reference on PubMed
    • View reference on publisher's website
  29. Mouton JW, den Hollander JG (1994) Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 38:931–936
    • View reference on PubMed
    • View reference on publisher's website
  30. Li C, Du X, Kuti JL, Nicolau DP (2007) Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 51:1725–1730
    • View reference on PubMed
    • View reference on publisher's website
  31. Tam VH, McKinnon PS, Akins RL, Rybak MJ, Drusano GL (2002) Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother 50:425–428
    • View reference on PubMed
    • View reference on publisher's website
  32. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J (2010) Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 36:332–339
    • View reference on PubMed
    • View reference on publisher's website
  33. Carlier M, Stove V, Roberts JA, Van de Velde E, De Waele JJ, Verstraete AG (2012) Quantification of seven beta-lactam antibiotics and two beta-lactamase inhibitors in human plasma using a validated UPLC-MS/MS method. Int J Antimicrob Agents 40:416–422
  34. Udy AA, Putt MT, Boots RJ, Lipman J (2011) ARC–augmented renal clearance. Curr Pharm Biotechnol 12:2020–2029
    • View reference on PubMed
    • View reference on publisher's website
  35. Hites M, Taccone FS, Wolff F, Cotton F, Beumier M, De Backer D, Roisin S, Lorent S, Surin R, Seyler L, Vincent JL, Jacobs F (2013) Case-control study of drug monitoring of beta-lactams in obese critically ill patients. Antimicrob Agents Chemother 57:708–715
    • View reference on PubMed
    • View reference on publisher's website
  36. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J (2011) The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 50:99–110
    • View reference on PubMed
    • View reference on publisher's website
  37. Roberts JA, Norris R, Paterson DL, Martin JH (2012) Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol 73:27–36
    • View reference on PubMed
    • View reference on publisher's website
  38. Sime FB, Roberts MS, Peake SL, Lipman J, Roberts JA (2012) Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care 2:35
    • View reference on PubMed
    • View reference on publisher's website
  39. Patel BM, Paratz J, See NC, Muller MJ, Rudd M, Paterson D, Briscoe SE, Ungerer J, McWhinney BC, Lipman J, Roberts JA (2012) Therapeutic drug monitoring of beta-lactam antibiotics in burns patients–a one-year prospective study. Ther Drug Monit 34:160–164
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement